View clinical trials related to Solid Tumor Cancers.
Filter by:Primary Objective: - To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of SAR245408 administered in combination with SAR256212 in adult patients with locally advanced or metastatic solid tumors. Secondary Objectives: - To characterize the global safety profile of SAR245408 in combination with SAR256212 - To evaluate the pharmacokinetic (PK) profile of SAR245408 and SAR256212 used in combination - To evaluate the objective response rate (ORR) and tumor volume change (for expansion cohort only) - To determine the immunogenicity of SAR256212 as administered with SAR245408
To evaluate the safety and tolerability of the veliparib/TMZ combination in subjects with solid tumors.